Ibrutinib is a drug which blocks signals in cancer cells which helps the cancer cell survive and grow resulting in the cells death and preventing the cancer from growing. Early clinical trials of ibrutinib in follicular lymphoma (FL) patients suggest it may reduce symptoms and ongoing clinical trials will determine if ibrutinib will extend life and slow the progression of FL compared to placebos and current offered treatment.If licenced in the UK, Ibrutinib could provide a novel alternative option for the treatment of patients with relapsed or refractory FL which may improve FL symptoms.
Ibrutinib for the treatment of relapsed or refractory follicular lymphoma
Interventions: Ibrutinib (Imbruvica)
Indications: Follicular lymphoma
Therapeutic Areas: Haematological Cancer and Lymphomas